CD8A and neoplasm: Autologous whole tumor antigens offer an unparalleled advantage as they allow DCs to process and present a broad range of tumor-associated antigens to stimulate strong, polyclonal, and long-term memory CD4+ and CD8+ T cell responses, potentially preventing tumor immune escape.